IAS 167A
Alternative Names: IAS-167ALatest Information Update: 28 Jan 2023
Price :
$50 *
At a glance
- Originator IASO BioMed
- Class Peptides
- Mechanism of Action 14-3-3 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Hypogonadism
Highest Development Phases
- No development reported Hypogonadism
Most Recent Events
- 28 Jan 2023 No recent reports of development identified for preclinical development in Hypogonadism in USA (PO)
- 28 Jan 2023 No recent reports of development identified for preclinical development in Hypogonadism in USA (SC)
- 13 May 2019 IAS 167A is available for licensing as of 30 Dec 2018. https://www.sec.gov/Archives/edgar/data/1662907/000149315219005827/form10-k.htm